NABRIVA THERAPEUTICS PLC's ticker is and the CUSIP is G63637105. A total of 3 filers reported holding NABRIVA THERAPEUTICS PLC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $3,000 | 0.0% | 5,500 | 0.0% | 0.00% | – |
| Q2 2020 | $3,000 | +50.0% | 5,500 | +52.0% | 0.00% | – |
| Q1 2020 | $2,000 | -50.0% | 3,619 | +44.8% | 0.00% | – |
| Q4 2019 | $4,000 | -20.0% | 2,500 | 0.0% | 0.00% | – |
| Q3 2019 | $5,000 | +66.7% | 2,500 | +66.7% | 0.00% | – |
| Q2 2019 | $3,000 | -40.0% | 1,500 | -22.1% | 0.00% | – |
| Q1 2019 | $5,000 | +66.7% | 1,925 | 0.0% | 0.00% | – |
| Q4 2018 | $3,000 | -72.7% | 1,925 | -54.5% | 0.00% | – |
| Q3 2018 | $11,000 | -76.6% | 4,230 | -68.8% | 0.00% | – |
| Q2 2018 | $47,000 | -61.2% | 13,539 | -43.7% | 0.00% | – |
| Q1 2018 | $121,000 | -38.9% | 24,030 | -27.2% | 0.00% | – |
| Q4 2017 | $198,000 | -61.1% | 33,030 | -46.9% | 0.00% | – |
| Q3 2017 | $509,000 | -8.0% | 62,202 | +17.8% | 0.00% | – |
| Q2 2017 | $553,000 | – | 52,807 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 191,028 | $462,000 | 0.08% |
| Sterling Investment Advisors, Ltd. | 5,000 | $12,000 | 0.00% |
| IFP Advisors, Inc | 0 | $0 | 0.00% |